Benzinga · Sep 4, 2026
Roth Capital Reiterates Buy on Equillium, Maintains $12 Price Target
Roth Capital analyst Adam Walsh reiterates Equillium (NASDAQ:EQ) with a Buy and maintains $12 price target.
EQ
NASDAQ · EQ
Equillium, Inc. Common Stock
Healthcare · Biotechnology
$2.11
Down-$0.31 (-12.81%)
Updated Sep 12, 2026, 12:34 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 47.6M
- P/E ratio
- -3.58
- Dividend yield
- 0.00%
- 52-week range
- $0.76 – $3.54
- Volume
- 554.05K
- Avg. volume
- 570.19K
Price performance
EQ price history
1M range · 20 trading sessions · Daily adjusted prices
EQ closed at $2.11 after 20 trading sessions, down 10.59% for the selected period.
- Last close
- $2.11
- Period change
- -10.59%
- Period low
- $2.11
- Period high
- $2.56
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $2.46 | $2.46 | $2.11 | $2.11 | 554.05K |
| Sep 10, 2026 | $2.54 | $2.69 | $2.41 | $2.42 | 397.61K |
| Sep 9, 2026 | $2.41 | $2.56 | $2.331 | $2.56 | 1.09M |
| Sep 8, 2026 | $2.20 | $2.47 | $2.17 | $2.41 | 597.9K |
| Sep 4, 2026 | $2.22 | $2.25 | $2.20 | $2.21 | 225.92K |
| Sep 3, 2026 | $2.26 | $2.31 | $2.18 | $2.22 | 152.57K |
| Sep 2, 2026 | $2.20 | $2.305 | $2.18 | $2.25 | 101.24K |
| Sep 1, 2026 | $2.25 | $2.26 | $2.185 | $2.205 | 161.3K |
| Aug 31, 2026 | $2.39 | $2.39 | $2.21 | $2.27 | 288.98K |
| Aug 28, 2026 | $2.46 | $2.46 | $2.33 | $2.39 | 232.76K |
| Aug 27, 2026 | $2.36 | $2.52 | $2.36 | $2.45 | 368.07K |
| Aug 26, 2026 | $2.18 | $2.47 | $2.15 | $2.36 | 698.73K |
| Aug 25, 2026 | $2.21 | $2.24 | $2.152 | $2.18 | 606.01K |
| Aug 24, 2026 | $2.31 | $2.31 | $2.175 | $2.20 | 326.8K |
| Aug 21, 2026 | $2.30 | $2.4641 | $2.24 | $2.31 | 557.35K |
| Aug 20, 2026 | $2.27 | $2.3327 | $2.21 | $2.27 | 242.52K |
| Aug 19, 2026 | $2.43 | $2.43 | $2.28 | $2.33 | 247.87K |
| Aug 18, 2026 | $2.45 | $2.55 | $2.32 | $2.35 | 710.43K |
| Aug 17, 2026 | $2.262 | $2.49 | $2.262 | $2.48 | 261.5K |
| Aug 14, 2026 | $2.03 | $2.37 | $1.96 | $2.36 | 538.71K |
Latest EQ news
The latest Smart Investors Daily articles mentioning EQ.
Stock researchCompany · Overview
EQ research
Overview
Company profile and research snapshot.
Company profile
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $1.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 4, 2026 | Roth Capital | Buy | — |
| Jul 13, 2026 | Piper Sandler | Overweight | — |
| Jun 2, 2026 | Roth Capital | Buy | — |
| May 28, 2026 | Roth Capital | Buy | — |
| May 28, 2026 | Leerink Partners | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 2, 2026
Equillium to Participate in Upcoming Investor Conferences
LA JOLLA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences: Cantor Global Healthcare Conference 2026Format: Fireside Chat & 1x1 MeetingsDate: Wednesday, September 9, 2026Time: 9:45 AM EDTWebcast Link: Here H.C. Wainwright 28th Annual Global Investment ConferenceFormat: Co
SeekingAlpha · Jul 22, 2026
Equillium: The Market Seems To Have Already Priced In Phase 1 Success
Equillium, Inc. underwent a pipeline reset after its lead asset failed, pivoting to GI diseases with EQ504 as the new flagship. Read more on EQ stock here.
Benzinga · Jul 13, 2026
Piper Sandler Initiates Coverage On Equillium with Overweight Rating, Announces Price Target of $20
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Equillium (NASDAQ:EQ) with a Overweight rating and announces Price Target of $20.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
